Butt, Glesby, Kapadia, Marks, Schackman
Hepatitis C infection is the leading cause of end stage liver disease and need for liver transplantation in this country. Current studies focus on treatment of HCV infection in special populations including people living with HIV, people who inject drugs (PWID), and veterans. This includes an R01-funded study of a randomized trial investigating a community-based strategy of HCV treatment in PWID as well as an ongoing cohort study, ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans). CCTU investigators also conduct ACTG studies of direct-acting antivirals for acute and chronic HCV infection. The Center for the Study of Hepatitis C, a multidisciplinary center involving Rockefeller University, Weill Cornell Medical College, and NewYork-Presbyterian Hospital, provides additional opportunities for translational research, access to a serum and tissue bank, and collaboration with experts in the field of virology and hepatitis treatment (e.g. 2000 Nobel laureate Dr. Charlie Rice). Additionally, Bruce Schackman, Ph.D., directs the Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH), a multi-institutional center of excellence funded by the National Institute on Drug Abuse. In addition to research and mentorship opportunities, CHERISH supports methodological consultation for researchers with an interest in hepatitis and substance use, a pilot grant program for early investigators, and health economics training opportunities.
Butt AA, Yan P, Shaikh OS, Lo Re V 3rd, Abou-Samra AB, Sherman KE. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study. J Hepatol. 2020;73(2):277-284.
Butt AA, Yan P, Aslam S, Sherman KE, Siraj D, Safdar N, Hameed B. Hepatitis C virologic response in hepatitis B and C coinfected persons treated with directly acting antiviral agents: Results from ERCHIVES. Int J Infect Dis. 2020 Mar;92:184-188.
Butt AA, Yan P, Aslam S, Abou-Samra AB, Sherman KE, Shaikh OS. Liver Fibrosis Progression and Mortality in Hepatitis B- and C-Coinfected Persons Treated With Directly Acting Antiviral Agents: Results From ERCHIVES. Clin Infect Dis. 2019 Dec 16:ciz1097.
Kapadia SN, Johnson P, Schackman BR, Bao Y. Hepatitis C treatment uptake by new prescribers after the introduction of direct acting antivirals. J Gen Intern Med. 2020 Mar; 35(3): 975-7.
Katzman C, Mateu-Gelabert P, Kapadia SN, Eckhardt BJ. Contact Tracing for Hepatitis C: The Case for Novel Screening Strategies as We Strive for Viral Elimination. Int J Drug Policy. 2019 Oct; 72:33-9.
Kapadia SN, Johnston CD, Marks KM, Schackman BR, Martin EG. Strategies for Improving Hepatitis C Treatment Access in the United States: State Officials Address High Drug Prices, Stigma, and Building Treatment Capacity. J Public Health Manag Prac. 2019 May/Jun;25(3):245-52.
Naggie S, Fierer DS, Hughes MD, Kim AY, Luetkemeyer A, Vu V, Roa J, Rwema S, Brainard DM, McHutchison JG, Peters MG, Kiser JJ, Marks KM, Chung RT; ACTG 5327 Study Team. Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. Clin Infect Dis. 2019 Jul 18;69(3):514-522.